SEBI Reg. Investment Advisor

Download App
Help Center Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Alembic Pharmaceuticals Ltd (APLLTD)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533573 NSE: APLLTD Pharmaceuticals & Drugs | Small Cap | Alembic Pharma Share Price

₹796.50 2.45 (0.31%)

As on 24-Jul'26 16:59

Alembic Pharmaceuticals Ltd (APLLTD)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533573 NSE: APLLTD Pharmaceuticals & Drugs | Small Cap | Alembic Pharma Share Price

₹796.50 2.45 (0.31%)

As on 24-Jul'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹15,656 Cr.
Current Price
₹796.5
52-Week Low / High
₹635 / 1,027
TTM EPS
₹34.3
TTM Sales
₹7,345 Cr.
Book Value per Share
₹288.7
P/E Ratio
23.20
Lower than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
2.76
Lower than its 5-year historical median
Price to Sales (P/S)
2.13
Lower than its 5-year historical median
EV/EBITDA
14.34
Lower than its 5-year historical median
Dividend Yield
1.51%
Profitability Efficiency
Return on Equity (ROE)
12.35%
Outperforms industry median
Return on Capital Employed (ROCE)
11.74%
Outperforms industry median
Return on Assets (ROA)
8.23%
Operating Profit Margin
15.3%
Net Profit Margin
9.13%
Gross Profit Margin
7.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
10.08%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
11.47%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
15.26%
Asset Quality
Promoter Holding
69.87%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹5,636 Cr.
Equity
₹39.3 Cr.
Face Value
₹2
All Time Low / High
₹34.00 / 1296.15

Alembic Pharmaceuticals stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Somewhat Good
Check detailed performance

Valuation

Undervalued

Check Valuation charts

Price Trend

Semi Strong
Check Price chart
Q.1 Is Alembic Pharmaceuticals Ltd a good quality company?
Alembic Pharmaceuticals Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Alembic Pharmaceuticals Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Alembic Pharmaceuticals Ltd vs industry peers?
Alembic Pharmaceuticals Ltd revenue CAGR is 6.37%, compared to the industry median CAGR of 5.34%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Alembic Pharmaceuticals Ltd?
Promoters hold 69.87% of the Alembic Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Alembic Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 3.1% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Alembic Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ28.9%22.2%22.7%23.3%26.3%11.3%7.4%13.4%13.5%11.7%-
Value Creation
Index ⓘ		1.10.60.70.71.0-0.2-0.50.20-0.1-

Growth Parameters ⓘ
Sales ⓘ3,1353,1313,9354,6065,3935,3065,6536,2296,6727,3457,345
Sales YoY Gr.--0.1%25.7%17.1%17.1%-1.6%6.5%10.2%7.1%10.1%-
Adj EPS ⓘ21.620.730.245.255.324.817.530.528.234.934.3
YoY Gr.--4.3%46.2%49.6%22.6%-55.2%-29.4%74.3%-7.5%23.8%-
BVPS (₹) ⓘ100.9117.8144.2170.8257.8266.5222.4245.1264.1288.7288.7
Adj Net
Profit ⓘ		4073895698511,088487344600555687675
Cash Flow from Ops. ⓘ3293128124491,46355272480388783-
Debt/CF from Ops. ⓘ0.32.31.43.90.31.10.90.513.61.7-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ9.9%6.4%9.1%10.1%
Adj EPS ⓘ5.5%-8.8%25.9%23.8%
BVPSⓘ12.4%2.3%9.1%9.3%
Share Price 3.1% -3.4% 4.8% -20.2%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		23.318.92328.726.39.57.213.111.112.611.9
Op. Profit
Mgn % ⓘ		19.819.721.826.427.416.512.6151515.315.2
Net Profit
Mgn % ⓘ		13.112.714.717.919.69.26.19.68.39.39.2
Debt to
Equity ⓘ		0.10.30.40.50.10.10.20.10.20.20
Working Cap
Days ⓘ		1591941821861811921888198110107
Cash Conv.
Cycle ⓘ		26323869708810520344743

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales3,1353,1313,9354,6065,3935,3065,6536,2296,6727,345
Operating Expenses ⓘ + 2,5202,5163,0793,3923,9134,4324,9455,2965,6696,227
Manufacturing Costs354315358471491500561561620685
Material Costs8888869931,0391,2571,4461,7091,7151,7931,984
Employee Cost 5596237479061,0511,1331,1691,4461,5621,732
Other Costs ⓘ 7206929819751,1141,3521,5061,5741,6931,825
Operating Profit ⓘ 6156158561,2141,4808747089331,0031,118
Operating Profit Margin (%) 19.6%19.7%21.8%26.4%27.4%16.5%12.5%15.0%15.0%15.2%
Other Income ⓘ + 335271487503294855
Exceptional Items ⓘ 000-44000013-67
Interest ⓘ 531827161850567994
Depreciation ⓘ 83105115157183287275273279319
Profit Before Tax ⓘ 5295417491,0001,368625355632707694
Tax ⓘ 122120157199253104131612523
Profit After Tax 4074215938011,115521342616582671
PAT Margin (%) 13.0%13.4%15.1%17.4%20.7%9.8%6.1%9.9%8.7%9.1%
Adjusted EPS (₹)21.421.931.044.058.326.517.431.329.734.3
Dividend Payout Ratio (%)18.70%18.30%17.70%22.70%24%37.70%46%35.10%37.10%35%

Valuation of Alembic Pharma - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 1,9022,2202,7193,2195,0675,2384,3704,8185,1915,675
Share Capital ⓘ 38383838393939393939
Reserves ⓘ 1,8652,1822,6813,1825,0285,1984,3314,7795,1525,636
Debt +897089281,7472004306364301,1961,341
Long Term Debt05004998872000000122
Short Term Debt8920842986104306364301,1961,219
Minority Interest00-1-290000-1-6
Trade Payables501759644626669706680736880835
Others Liabilities ⓘ 3193766616281,026856378357444741
Total Liabilities ⓘ 2,8114,0644,9526,1926,9617,2306,0646,3417,7098,586

Fixed Assets

Net Fixed Assets ⓘ +7999931,1581,5521,7881,7982,3982,5472,5243,081
Gross Block9501,2421,5232,1322,5452,8403,4683,8754,1174,897
Accumulated Depreciation1512493645817571,0421,0691,3291,5941,816
CWIP ⓘ 3961,0101,5511,8462,1832,304601524837683
Investments ⓘ 504249182361189693127141
Inventories6337349671,1881,4861,6101,4751,6442,2882,511
Trade Receivables3395264898653498071,0461,0251,4001,466
Cash Equivalents 1609020681106698212790203
Others Assets ⓘ 434668532643814523364382443501
Total Assets ⓘ 2,8114,0644,9526,1926,9617,2306,0646,3417,7098,586

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 3293128124491,46355272480388783
PBT ⓘ 5295417491,0001,368625355632707694
Adjustment ⓘ 8387118278102418488287374449
Changes in Working Capital ⓘ -166-181112-593238-367-58-96-921-257
Tax Paid ⓘ -118-135-166-236-245-123-61-20-71-104
Cash Flow From Investing Activity ⓘ + -486-884-756-732-839-372-448-321-568-506
Capex -491-807-763-734-659-424-442-316-554-493
Net Investments 40-140-18648-7-7-21-14
Others ⓘ 1-77223751271
Cash Flow From Financing Activity ⓘ + -12950359155-597-217-262-438444-164
Net Proceeds from Shares ⓘ 000073400000
Net Proceeds from Borrowing ⓘ -55000000000142
Interest Paid ⓘ -5-26-70-111-73-52-50-49-79-88
Dividend Paid ⓘ -90-91-91-3260-275-197-157-216-216
Others ⓘ -29120220592-1,259110-16-231739-2
Net Cash Flow ⓘ -286-69115-12827-371445-37113

Financial Ratio

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)23.2520.422426.9726.9110.117.1213.411.6312.35
ROCE (%)28.8722.1522.6623.326.2811.257.4413.4213.5111.74
Asset Turnover Ratio1.150.910.870.830.820.750.852.171.911.75
PAT to CFO Conversion(x)0.810.741.370.561.311.062.121.30.151.17
Working Capital Days
Receivable Days40.1050.4047.1053.6041.1039.8059.8028.103336.70
Inventory Days7079.7078.9085.4090.50106.5099.6042.3053.5061.50
Payable Days219.30259.50258.10223187.90173.50148150.60164.40157.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Alembic Pharmaceuticals Ltd FAQs

The current trading price of Alembic Pharma on 24-Jul-2026 16:59 is ₹796.5.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Jul-2026 the market cap of Alembic Pharma stood at ₹15,656.3 Cr

The latest P/E ratio of Alembic Pharma as of 23-Jul-2026 is 24.45.

The latest P/B ratio of Alembic Pharma as of 23-Jul-2026 is 2.79.

The 52-week high of Alembic Pharma is ₹1,027 and the 52-week low is ₹635.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Alembic Pharma is ₹6,651 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Alembic Pharmaceuticals Ltd is a average quality company.

The key valuation ratios of Alembic Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Alembic Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Alembic Pharmaceuticals Ltd

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.

With an emphasis on innovation and technology, the company has established a state-of-the-art research facility - Alembic Research Centre (ARC)-including formulation research, and huge bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad.

Business area of the company

The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.

Awards and recognition

  • Forbes India Awards Mr Pranav Amin and Mr. Shaunak Amin as ‘NextGen Entrepreneurs of the Year’
  • 1st Runner up Position in Job Safety Analysis(JSA) - at CII Industrial Safety Summit 2016
  • The company’s Commitment towards Risk Management honoured at Gujarat Seminar and Conclave on Risk Management.
  • The company’s MDs honoured with 'Transformational Leader Award'
  • The company won 'HR event of the Year' and 'Outstanding contribution to the cause of Education' at the 'Gujarat Best Employer Brand Awards 2017'
  • The company won 'HR event of the Year' at the 'Gujarat Best Employer Brand Awards 2017'

Milestones

  • 1907: Started manufacturing tinctures and alcohol at Vadodara.
  • 1940: Started manufacturing cough syrup, vitamins, tonics and sulphur drugs.
  • 1961: Lal bahadur Shastri inaugurates the Penicillin plant.
  • 1967: Bulk manufacturing of Vitamin B12.
  • 1971: Erythromycin manufactured for the first time in India.
  • 1972: Althrocin a brand of Erythromycin launched.
  • 1997: Althrocin becomes top selling brand in India.
  • 1999: Alembic starts production of synthetic organic API.
  • 2000: Gets ISO 14000 certification for its facilities at Vadodara.
  • 2001: Starts manufacturing of Cephalosporin C.
  • 2007: Acquisition of non - oncology business of Dabur Pharma Ltd.
  • 2009: Addressed chronic therapies through multiple marketing divisions.
  • 2010: ANDA’s total filed 38. DMF total filed to 53 and get approval for 15.
  • 2011: Pharmaceutical Business demerged from Alembic - APL Listed.
  • 2012: Launched Dermatology division in domestic market with 8 products.
  • 2013: Launched first NDA with a partner. Commenced filing in EU, Australia and Brazil.
  • 2014: Formed a JV in Algeria- Alembic MAMI SPA to explore African market.
  • 2015: Launched Aripiprazole on Day-1. Established the U. S front-end, transition to own marketing in the U.S.
  • 2016: Formed JV 60:40 with Orbicular - “Aleor Dermaceuitical Limited” for developing Dermatology Products for international markets.
  • 2017: Shri. Vijay Rupani - Hon’ble Chief Minister of Gujarat, inaugurates the manufacturing facility for Oncology medicines (oral solids and liquid injectable vials).
  • 2017: Acquired Orit Laboratories LLC, USA.
  • 2018: FDA approved Aleor’s dermatology facility.
  • 2018: Highest ever investment commitment across four new manufacturing facilities.
  • 2019: FDA approves Oncology oral solid facility.
  • 2019: Formed a JV, to enter China.
  • 2020: US front-end achieved milestone of $ 250 Mn Sales in 2019-20.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: